…4.0 m/s or a valve area < 1.0 cm² with a mean gradient ≥ 40 mmHg. Fluid responsiveness Static measures such as the…

…over several weeks and may recur when the statin is reintroduced. The temporal relationship is clinically informative: Symptoms develop after treatment initiation or dose escalation…

…low dose, or low intensity lipid lowering therapy: • Start high potency, high dose statin therapy (Class I recommendation). • Immediate combination with ezetimibe can be considered…

…ezetimibe Approximately 38% reduction PCSK9 inhibitor added to statin therapy Approximately 60% reduction Inclisiran, with or without statin therapy Approximately 50% reduction The absolute reduction…

…background statin therapy 18% Fixed dose combination with ezetimibe 38% Pooled analyses across different background therapies 17%–25% In patients with atherosclerotic vascular disease or…

…countries as an adjunct to diet and maximally tolerated statin therapy in patients with heterozygous familial hypercholesterolaemia or ASCVD who require further LDL C lowering…

…50% from baseline. In patients who experience a recurrent atherothrombotic or cardiovascular event within 2 years while receiving maximally tolerated statin based treatment, an LDL…

…Indications PCSK9 inhibitors are used as additional lipid lowering therapy in patients whose LDL C remains above the recommended goal despite maximally tolerated statin therapy…

…Erosion: Responsible for up to 30% of ACS cases, plaque erosion is increasingly recognized in the modern era of high intensity statin therapy. Unlike rupture…

…coronary vasospasm, microvascular dysfunction, or combinations of these mechanisms. Drug selection can therefore be tailored to the suspected mechanism. No antianginal class has demonstrated consistent…

…Thus, even a modest absolute reduction may be clinically important in individuals at high or very high risk. Prolonged exposure to lower LDL C concentrations…